Drug FCN-159 vs chemo for children with low-grade glioma and BRAF change
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests whether a new oral drug called FCN-159 works better than standard chemotherapy for children and teens with a slow-growing brain tumor (low-grade glioma) that has a specific change in the BRAF gene. The goal is to see if FCN-159 can shrink the tumor or stop it from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Ages 2 to 17 years old
- Diagnosed with a low-grade (slow-growing) brain tumor called low-grade glioma, confirmed by tissue sample
- Your tumor has a specific change in the BRAF gene (either a BRAF V600E mutation or a KIAA1549-BRAF fusion)
- You need treatment because the tumor is growing, came back after surgery, or cannot be fully removed
- The tumor can be measured on an MRI scan and is at least 1 centimeter across
- You have not received certain cancer drugs or vaccines recently, and have not taken drugs like selumetinib or dabrafenib before
- You are generally well enough to carry out daily activities (performance score 70 or higher)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted therapy (dabrafenib and trametinib) and immunotherapy (nivolumab) for children and young adults with certain BRAF gene changes in their glioma. It aims to see if this drug combination can shrink tumors or stop them from growing.
This trial tests two targeted drugs (dabrafenib and trametinib) for children and young adults with a specific type of low-grade brain tumor that has a BRAF V600 mutation. The drugs work by blocking signals that help the tumor grow.
This trial studies whether the targeted drug selumetinib works better than standard chemotherapy (carboplatin and vincristine) for children and young adults with a specific type of low-grade glioma (grade 1 or 2). It may help shrink tumors and slow growth while comparing side effects between the two treatment approaches.
This Phase 2 study tests tovorafenib, a targeted cancer medicine, in children and young adults whose tumors have specific BRAF or RAF changes. It is for cancers that have come back or grown despite previous treatment, with measurable signs on scans.
This trial is testing a combination of two drugs, vinblastine and tovorafenib, for children and young adults (up to age 25) whose low-grade glioma has come back or worsened after prior treatment. It is for people whose tumor has a specific change in a gene called BRAF or CRAF.
This study tests an experimental medicine called tovorafenib for children and young adults (6 months to 25 years) with Japanese ancestry whose low-grade brain tumors have returned or grown after prior treatment. The medicine targets tumors with a specific BRAF genetic change.
Hear when a new Low-grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.